Understanding the genetic makeup of neuroblastic tumors and their impact on treatment outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze the genetic and biochemical characteristics of neuroblastic tumors to determine how these factors influence tumor aggressiveness and treatment options. It involves collecting tumor and marrow specimens, as well as blood samples, to study the molecular-genetic makeup of the tumors and correlate these findings with clinical outcomes. The research will also explore the signaling pathways of neuroblastic tumors in relation to embryonic neuroectodermal cells, providing insights into potential therapeutic targets.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Neuroblastic tumors diagnosed in accordance with the International Neuroblastoma Staging System

OR

* Clinically suspected neuroblastic tumors.

PK DRAW INCLUSION CRITERIA (FOR PK DRAWS ONLY):

PK Draw Inclusion Criteria

* Patients who receive naxitamab as part of their standard of care

Exclusion Criteria:

* None

Where it's running

• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Nai-Kong Cheung, M.D., Ph.D. — Memorial Sloan Kettering Cancer Center
• Study coordinator: Nai-Kong Cheung, M.D., Ph.D.
• Phone: 646-888-2313

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neuroblastoma patients' genomic and biological profile study

  This multicenter, prospective study tests profiles from blood, tumor tissue, and bone marrow to understand neuroblastoma in diagnosed, relapsed, or refractory patients.

  Recruiting at 35 sites Istituto Giannina Gaslini · Ancona and 34 other locations · NCT07881172

• CIML-NK Cells to Treat Neuroblastoma in Relapsed or Refractory Patients

  We’re testing whether donor-derived cytokine-induced memory-like NK cells can be safely given with dinutuximab to kids and young adults whose neuroblastoma has come back or not responded to treatment.

  Recruiting Phase 2 Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07635056

• Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors

  This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07584499

• Tracking tumor DNA over time in neuroblastoma

  This project tests whether regular blood tests measuring circulating tumor DNA and molecular residual disease can track disease status and detect relapse earlier in children with neuroblastoma.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07516678

• Anti-GD2-800CW imaging to highlight neuroblastoma during surgery

  This trial will test whether a fluorescent antibody called anti-GD2-800CW can safely help surgeons see and remove neuroblastoma in children ages 1 to 18.

  Recruiting Phase 1/2 Princess Maxima Center for Pediatric Oncology · Utrecht · NCT07399821

• B7-H3 CAR T cells for relapsed or refractory solid tumors in children and young adults

  This study tests a new B7-H3 CAR T cell therapy to see if it is safe and can help kids and young adults whose solid tumors have come back or stopped responding to standard treatments.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07358260

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.